Imatinib Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IAIN/0039/G 
This was an application for a group of variations. 
12/12/2022 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IA/0038 
B.II.b.4.a - Change in the batch size (including batch 
21/10/2022 
n/a 
size ranges) of the finished product - Up to 10-fold 
Page 2/14 
 
 
 
 
 
 
 
 
compared to the originally approved batch size 
IA/0037 
A.5.b - Administrative change - Change in the name 
20/09/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IA/0036 
B.III.1.a.4 - Submission of a new/updated or 
05/09/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Deletion of certificates 
(in case multiple certificates exist per material) 
IB/0035/G 
This was an application for a group of variations. 
23/06/2022 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0033/G 
This was an application for a group of variations. 
06/01/2022 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Other variation 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IA/0034 
A.7 - Administrative change - Deletion of 
22/12/2021 
manufacturing sites 
Annex II and 
PL 
IB/0032/G 
This was an application for a group of variations. 
26/08/2021 
29/09/2021 
SmPC and PL 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0031 
B.III.1.a.3 - Submission of a new/updated or 
04/02/2021 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0030 
B.I.b.2.a - Change in test procedure for AS or 
14/01/2021 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0029 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/08/2020 
12/08/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0028 
B.II.b.2.a - Change to importer, batch release 
16/06/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0027 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/08/2019 
13/08/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0026 
B.II.b.2.a - Change to importer, batch release 
25/02/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
T/0025 
Transfer of Marketing Authorisation 
28/01/2019 
14/02/2019 
SmPC, 
Labelling and 
PL 
Page 5/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/10/2018 
14/02/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0024/G 
This was an application for a group of variations. 
11/10/2018 
14/02/2019 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
R/0020 
Renewal of the marketing authorisation. 
22/02/2018 
19/04/2018 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Imatinib Accord in the approved indication remains 
favourable and therefore recommended the renewal of the 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
marketing authorisation with unlimited validity. 
IAIN/0022 
B.III.1.a.3 - Submission of a new/updated or 
22/02/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/02/2018 
19/04/2018 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0019 
A.5.b - Administrative change - Change in the name 
21/09/2017 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0018/G 
This was an application for a group of variations. 
21/09/2017 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.c.3.a - Change in test procedure for the 
immediate packaging of the AS - Minor changes to 
an approved test procedure 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/05/2017 
19/04/2018 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
Page 8/14 
 
 
 
 
 
 
 
IA/0016/G 
This was an application for a group of variations. 
20/04/2017 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/03/2017 
04/05/2017 
SmPC and PL 
The marketing authorisation was extended to the 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/12/2016 
11/01/2017 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Labelling and 
PL 
indications of “adult patients with newly diagnosed 
Philadelphia chromosome (bcr-abl) positive (Ph+) chronic 
leukaemia (CML) for whom bone marrow transplantation is 
not considered first line treatment” and “adult patients with 
Ph+ CML in chronic phase after failure of interferon-alpha 
therapy, or in accelerated phase”. Although similar to 
Tasigna, the application fulfilled the requirement for 
derogation of market exclusivity foreseen in Article 8(3)(a) 
of Regulation (EC) No 141/2000. 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0014/G 
This was an application for a group of variations. 
02/12/2016 
04/01/2017 
SmPC 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0012 
C.I.z - Changes (Safety/Efficacy) of Human and 
28/09/2016 
04/01/2017 
SmPC 
Veterinary Medicinal Products - Other variation 
IAIN/0011 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/07/2016 
04/01/2017 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0010 
A.5.b - Administrative change - Change in the name 
22/02/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0009/G 
This was an application for a group of variations. 
25/01/2016 
04/01/2017 
SmPC, 
Labelling and 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IAIN/0008/G 
This was an application for a group of variations. 
25/01/2016 
04/01/2017 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 11/14 
 
 
 
 
 
 
 
 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0007/G 
This was an application for a group of variations. 
01/06/2015 
16/11/2015 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0006/G 
This was an application for a group of variations. 
05/12/2014 
16/11/2015 
SmPC and PL 
To update section 5.3 of the SmPC in order to reflect 
the results of a juvenile development toxicology 
study. In addition, the MAH took the opportunity to 
reflect in the PL the adverse drug reaction of 
“bleeding in the eyes” which was already listed in 
section 4.8 of the SmPC. Furthermore, the PI is 
being brought in line with the latest QRD template 
version 9.0. 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
 
To update section 4.8 of the SmPC in order to 
include the term "Drug rash with eosinophilia and 
systemic symptoms" (DRESS) under the SOC Skin 
and subcutaneous disorders with a frequency of 
unknown further to the PRAC request following the 
assessment of a cumulative review of cases of 
DRESS. The Package Leaflet updated accordingly. 
Furthermore, the MAH took the opportunity of this 
variation to add and correct information in the PL to 
bring it in line with the SmPC. Editorial changes were 
also introduced in the SmPC 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
10/11/2014 
16/11/2015 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0004 
B.II.b.2.a - Change to importer, batch release 
14/05/2014 
n/a 
arrangements and quality control testing of the FP - 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0003 
B.II.b.2.c.2 - Change to importer, batch release 
01/10/2013 
01/09/2014 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Including batch control/testing 
IAIN/0001 
C.I.8.a - Introduction of or changes to a summary of 
30/08/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 14/14 
 
 
 
 
 
 
 
 
 
 
 
 
